AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine



VIENNA, July 24, 2014 /PRNewswire via COMTEX/ -- VIENNA, July 24, 2014 /PRNewswire/ --

What: AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson's disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson's research community.



When: Thursday, July 31, 2014

11.00 am EST (Eastern Standard Time)

03.00 pm UTC (Coordinated Universal Time)



Where: New York Marriott East Side Hotel

525 Lexington Ave, New York

Room Morgan A

Live webcast link: http://totalwebcasting.com/view/?id=affiris



Who: Walter Schmidt, PhD: CEO & Co-founder, AFFiRiS AG

Todd Sherer, PhD: CEO, The Michael J. Fox Foundation

Prof. Achim Schneeberger, MD: CMO, AFFiRiS AG



If you are unable to attend the press conference, please visit the aforementioned web link for a live webcast. An embedded message board will allow you to participate in the Q&A. A recording of the conference will be made available immediately after the press conference at http://totalwebcasting.com/view/?id=affiris

About AFFiRiS AG

Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines (and more) for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. AFFiRiS currently employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria ( http://www.affiris.com ).

http://www.marketwatch.com/story/med...ine-2014-07-24